Articles tagged with: Ricolinostat
Press Releases»
Interim Results from Phase 1b/2 ACE-MM-102 and Phase 1a/1b ACE-MM-200 Studies to be Presented at the 57th Annual Meeting of the American Society of Hematology
Boston (Press Release) Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, today announced that it will present clinical data demonstrating promising tolerability and overall response rates from a Phase 1b/2 study of a selective HDAC6 inhibitor, ricolinostat (ACY-1215), in combination with pomalidomide (Pomalyst®, Celgene) and dexamethasone for the treatment of relapsed-and-refractory multiple myeloma (ACE-MM-102 study). These data …
News, Opinion»

A new year is upon us. I hope it has started well for everybody, and that all had a great holiday season!
The last few weeks of 2014 were a happening time for the multiple myeloma community. The short span of time witnessed the publication of updated criteria for the diagnosis of multiple myeloma from the International Myeloma Working Group (IMWG). In addition, the 56th annual meeting of the American Society of Hematology (ASH) took place in San Francisco, with literally hundreds of myeloma-related oral and poster presentations.
Therefore, it is again …
News»

Monday was the third day of this year’s meeting of the American Society of Hematology (ASH). The day was filled with oral presentation sessions from early in the morning until into the evening.
In the afternoon and early evening, there were six oral presentation sessions devoted solely to multiple myeloma and a number of other myeloma-related presentations scattered about the afternoon. The topics of these presentations ranged from the biology of myeloma to treatment options for newly diagnosed, relapsed and refractory, and older patients.
This ASH update highlights most of the oral …
News»

Yesterday was the second day of the American Society of Hematology’s (ASH) annual meeting, which is being held in New Orleans.
As on Saturday, myeloma-related presentations were once again made during several sessions throughout the day.
Experts who missed the education session on Saturday had the opportunity to attend the session again early Sunday morning.
One myeloma study was presented during the plenary session in the early afternoon. The six presentations in this session covered all blood cancers and are considered particularly important studies.
The myeloma study included in this session was …
News»

This article is the second in The Beacon’s ‘preview’ series about myeloma research that will be presented at the American Society of Hematology (ASH) meeting in early December.
Abstracts for the ASH presentations are now available; these abstracts contain preliminary data, and updated data will be presented at the meeting.
The Beacon's ASH preview articles, which will be published over the next couple of weeks, will highlight the most interesting myeloma-related studies that will be presented at the meeting.
The first preview, which was published last …
News»

In a recent review article published in the journal Clinical Cancer Research, two myeloma experts from the Dana-Farber Cancer Institute, Dr. Nikhil Munshi and Dr. Kenneth Anderson, review the latest strategies in the treatment of multiple myeloma.
In their article, the experts discuss newer therapies that appear to be promising in clinical and preclinical studies.
According to the physicians, combination therapies that specifically target a patient’s genetic form of the disease will be required for long-term disease control and ultimately a cure.
Some Historical Perspective
In their review article, Drs. Munshi and …
News»

Monday was the third and next-to-last day of the 2012 American Society of Hematology (ASH) annual meeting.
It also was the busiest day of the meeting in regard to myeloma-related research.
The day ended with a poster session in the evening that featured over 1000 posters displayed throughout a large conference hall. More than a hundred of the posters reported on the results of myeloma-related research.
Compared to the research summarized during oral presentations, the findings in poster summaries generally are in earlier stages of development. They may involve laboratory research, clinical …